[go: up one dir, main page]

BE647556A - - Google Patents

Info

Publication number
BE647556A
BE647556A BE647556A BE647556A BE647556A BE 647556 A BE647556 A BE 647556A BE 647556 A BE647556 A BE 647556A BE 647556 A BE647556 A BE 647556A BE 647556 A BE647556 A BE 647556A
Authority
BE
Belgium
Prior art keywords
acid
tome
desc
page number
clms page
Prior art date
Application number
BE647556A
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to BE647556A priority Critical patent/BE647556A/fr
Publication of BE647556A publication Critical patent/BE647556A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

  

   <Desc/Clms Page number 1> 
 
 EMI1.1 
 



  11 A01dl IpI11on-aminooaprofqu. 00.. agent d. tralttawnt d9µ tumeurs mlipesq des infectiones des 1ntlumat1oDI et des trau matismes" 
La présente invention se rapporte à   l'utilisation   de   l'acide   epsilon-aminocaproïque, comme agent pour le trait..   sont   des états consécutifs douloureux de tumeurs malignes com- me par exemple le cance,r les traumetismes, les affection$ pa- remchymateuses et les inflammations de nature variable  on res-   pectivement   comme agent curateur des manifestations pathologiques suscitant ces   état@     consécutifs   douloureux. 



     L'acide   epsilon-aminocaproique, sur la   base   de consi- 
 EMI1.2 
 d'rat1oN th'or1qu...t d'expérienoes, n'était jusqu'à présent   utilisé   en médecine que pour le traitement d'un nombre limité de   manifestations     pathologiques,     En     raison   de   ses     propriétés    orne inhibiteur de fomentation on a utilisé l'acide   epsilon*   aminocaproïque par exemple pour arrêter les   saignements   après 
 EMI1.3 
 l'emploi de t1br1nol711ne, de streptokinase ou de streptodoma- se, de   saignements   gynécologique et de   tous     les   autres   saigne-     ments   internes,

   en outre pour la traitement   d'états   de choc à la suite d'anaphylaxis, d'allergies, en particulier de celles 

 <Desc/Clms Page number 2> 

 
 EMI2.1 
 ;'elU, type el. 1..tom.d. r'act1oa "ralenti.. 'ou:," .1xtt::,t.o.1t'.>:;:   maladie   du sérums états   Allergiques dans   les maladies infectieu- ses,   hypersensibilité aux     médicaments et     également   asthme)et 
 EMI2.2 
 ,; loue les état# -".:

   ' - .,:,¯...:-:11':,:'->,'::>,.¯" .f # ' #####' i rt V-'- L'acide epeilon-aminooaproique apporte ici un eoulaeewent  S , *) intervient rapidement, lequel peut être 111. , profit pour 1R* - "#** troduire une thérapie nedicamenttire active phytiqueneat #  'iï ## outre l' acid..ps110n..aminocaprotque *test avéré convenir le traitement des   lésions   de   rayons!   et nucléaires, 
On   vient   de découvrir présentement que l'acide opsi- 
 EMI2.3 
 lon-am1nocaprotque convient pour le traitement, dot;

   nuire ,,<##? '##' pathologiques suivantes qui jusqu * présent notaient pM ''¯.. ' patholo1que.lu1 Tant,. qui et pl".eut ''''ai8nt' w #'è'ô**1   connues   comme donnant une   réponse/pour     1,.quelle.   il n'étair   'pu   possible de prévoir qu'elles donneraient une répones, d'après 
 EMI2.4 
 les propriété* connues de l'acide ep.ilon.w.nooaprof411.1"'::5'/it':,ii/{ ' urétrite non spécifique) lésions par8nch1mat.Ul8' et W1...;:.i<{/:

   tions d'organes parenchymat eux comte les lésions d...8U\\1....,f'' ' foie, l'ictère de longue durée de toute gtnese, néphïit è a*J * se, oho1801.ti t., cholocystophatie# colique biliaire, ft....1Ii":P;','"   'et     neurite,   'tata   douloureux   dans le   cas   de   carcinome   à croissas- ce infiltrant* et   de métastases,   douleur de blessures, distor-   sion     douloureuse,   luxation, fracture des os, brûlures, épanche-   , lient     d'articulation,   hémarthrose, commotion cérébrale, cedées 
 EMI2.5 
 ' et épanchement de toute genèse defQuiaee eonftitidn, néphrctt - ascites, cedème thermique et   d'origine     solaire),   songélations,

     piqûres   dinsectes, morsure   de serpent .(pour   le   soutien de   la   thérapie     spécifique   et   cala.1'   la   douleur),   congestion dans la 
 EMI2.6 
 ';" région de la petite circulation, #dèae pulmonaire ÏM yl É traitement du compoeut central et du Composant L'ut1U.&tioQ de l'acide epeilOB-aMcapM: , le soulagement des états douloureux après des emiumélt" est particul16rtlllnt remarquable et effectif t couvent, par seule injection de 10 cm3   d'une   solution à 5%on   obtient   en 

 <Desc/Clms Page number 3> 

 
 EMI3.1 
 lit camps (souvent tn qv..1C\a..,,',.'oÍ\4',lil: .,' ,,:,'Ol,' da la , , t ;1 y:

   . 4 ;:¯V. , e < .""'..".. au,xr. ,.'xrir ,4 ou, arxn dan ur,artur ..odrx', après x p oaian d ,x hdx r a R , . ,; ,t.. ;, r nt:u,an., non artaar . ionda . taraf ât rlrxi ut w'dbi; ,,tü ,,, .-,. 



  ,1 t acide epsilon-aainoeaproïque, dans le d r '[i'r"i . nrt# ore na rru,r ân i ba,i'xm ,-tU.,'!.',/, ' ,, , . , somme th'r.peut,1 que ' causal. Tout xuaai ruâaNs intupli- cible" t apr.. 1  oonnaisaandtt actutllaa aur lt  de d'acti0.0 vite d. 3.' &0141 #pailon-aminooaprolqut, est 1' activité 4naisio, .1q,uI dans le ou des douleurs Caus 4 es par !## bltasurea, les , distorsions, les luxation., l,. fraoturet, 1   plaie  de bru lurll, ItO, ....,,;,j' i!'::,';jJ;;'0.1\f0;J .':'. 



  L. do..,e ., 1& 'torrae 4 h.i,t:U..'at1n"ï. \'aOtc!..,...:t silon-aminocaprolque s'tabliesent chaque fois d'après les circonstances, En particulier pour calmer la douleur, ou lorsque pour d'autres   raisons   on   désira     une entrée     l'action   particulièrement rapide ou   particulièrement     intense (choc,   
 EMI3.2 
 attaque d'asthme, colique biliaire, empoisonnements, o*4èmo pulmonaire), on administra 10,0 cm3   ,4 'une     solution   aqueuse à   par   voit   Intraveineuse     (la     moitié dans la cas de  enfants ),   Pour toutes les autres indications   citées     il suffit en général,

  '   en plus d'une injection   intraveineuse initiale de   10 cm3   d'une   solution à 5% donner trois fois par   jour =4   tablette à 0,25g pour maintenir une   action   durable;   il peut toutefois   s'averer nécessaire de   répéter     l'injection     intraveineuse     toutes   les   24     heures   à   48 heures,

       Les     plaies     duos   à   des     brûlures   s'é- pithlisent particulièrement rapidement   sous un bandage     avec   
 EMI3.3 
 un onguent a 2% d'acide epsilon-aminooaprofe.ua (ayant une basa exempte de   graisse),     On   doit toutefois, tout   comme   les ecxé- mas, les traiter non pas uniquement avedc un onguent à 2% d'aci- 
 EMI3.4 
 de Ip811on-am:Lnocaprofqul.'. Mais toujours en combinaison pare , t 'ra1e-oral.-10c al..".

    :;+:i, 

 <Desc/Clms Page number 4> 

 
 EMI4.1 
 a oanetsti qus 1let' peut ri;tv ernridrablrtbv le   dosage   et que   dans     des     indications     déterminées on     peut   attein- dre des activité étonnament augmentées   lorsqu'on     applique   l'a- 
 EMI4.2 
 aide epsilon-minocaprotque en trosvbislairoli et our tv de ''¯' composée se décomposant facilement tà,:,Iivo a ours consti- ''''#;' tuants, ave* des substance$ à aatxvitl larqur. - v .:. 



  Par exemple, il faut stttltatnt dans otrtaints eze conatances seulement 2 à 10% de la qu&ntitd 'cornaâ 'd t toid4 #pflilon-aainocaproîqu lorsqu'on l'adadnistrs mélangé dans le rapport molaire avec de   l'acide   alpha-phéaylbutyzique, Au lieu du   mélange   on peut naturellement   aussi   employer le composé des deux   substances,

       11 acide-*   lon-aminocaproïque
En vue du traitement de   certaines   maladies des os et des articulations et dans les   états   douloureux   dans   la   région   de   l'épine   dorsale supérieure   s'est     avérée   un agent particu- librement approprié une solution   d'injection   de 25 mg d'acide 
 EMI4.3 
 nicotinique et de 500 mg d' acide epiilo-aminocaprolque in aqua par 10 cm3, Les actions   secondaires     désagréables de     l'acide   nicotinique   (crampes   abdominales et prurit)

   ne se manifestent   pas     nous   cette forme   d'administration*     Comme     soutien   de la thérapie on peut en outre administrer un   mélange     molaire   d'acid 
 EMI4.4 
 de opsiloamminocaprotque avec de la b<tâ-M<thylta<-Mdi* ne ou de l'acide nicotinique par   rôle     oral*@     On   obtient des résultats   similaires   dans   le   cas de 
 EMI4.5 
 la combinaison de l'acide epsilonaminooaprotqud AVOO l'urée, " ;f la choline ou la bétatne perep*Ctiv ent lors de l'application ;; de leurs composée correspondant## leure compote corrwepondMtx.. rK;

   it 8 Y 8 li D 1 C d '1 ' Q ! !i . '-- ' "ll 
1. préparation contenant de l'acide apsilonsaminne- caproïque   comme     agents   pour la   thérapie   symptomatique   ou causale   

**ATTENTION** fin du champ DESC peut contenir debut de CLMS **.



   <Desc / Clms Page number 1>
 
 EMI1.1
 



  11 A01dl IpI11on-aminooaprofqu. 00 .. agent d. tralttawnt of mlipesq tumors of infections of 1ntlumat1oDI and trauma "
The present invention relates to the use of epsilon-aminocaproic acid, as an agent for the treatment. Are consecutive painful conditions of malignant tumors such as for example cance, r traumetisms, par-remchymal diseases. and inflammations of variable nature, respectively, as a curative agent of the pathological manifestations giving rise to these consecutive painful conditions.



     Epsilon-aminocaproic acid, on the basis of
 EMI1.2
 of rat1oN th'or1qu ... t experience, was until now used in medicine for the treatment of a limited number of pathological manifestations, Due to its properties as an inhibitor of fomentation has been used 'epsilon * aminocaproic acid for example to stop bleeding after
 EMI1.3
 the use of t1br1nol711ne, streptokinase or streptodoma, gynecological bleeding and all other internal bleeding,

   also for the treatment of shock states following anaphylaxis, allergies, especially those

 <Desc / Clms Page number 2>

 
 EMI2.1
 ; 'elU, type el. 1..tom.d. react1oa "slowed down .. 'or :," .1xtt ::, t.o.1t'.>:;: serum disease Allergic states in infectious diseases, hypersensitivity to drugs and also asthma) and
 EMI2.2
 ,; rent state # - ".:

   '-.,:, ¯ ...: -: 11':,: '->,' ::> ,. ¯ ".f # '#####' i rt V -'- Epeilon acid -aminooaproic brings here a eoulaeewent S, *) intervenes quickly, which can be 111., benefit for 1R * - "# ** to produce an active drug therapy phytiqueneat # 'iï ## besides the acid..ps110n..aminocaprotque * test proven to be suitable for treatment of radiation injuries! and nuclear,
It has just been discovered that opsi-
 EMI2.3
 lon-am1nocaprotque is suitable for processing, dot;

   harm ,, <##? '##' following pathologies which until now noted pM '' ¯ .. 'patholo1que.lu1 Tant ,. which and pl ".eut '' '' ai8nt 'w #' è'ô ** 1 known to give a response / for 1, .which. it was not possible to predict that they would give a response, d 'after
 EMI2.4
 the known properties * of the acid ep.ilon.w.nooaprof411.1 "':: 5' / it ':, ii / {' non-specific urethritis) lesions by8nch1mat.Ul8 'and W1 ...;:. i <{/:

   tions of parenchymal organs count lesions of ... 8U \\ 1 ...., f '' 'liver, long-term jaundice of any genesis, nephiit è a * J * se, oho1801.ti t ., cholocystophatia # biliary colic, ft .... 1Ii ": P; ','" 'and neuritis,' tata painful in the case of invasive growth carcinoma * and metastases, pain from wounds, distortion painful, dislocation, bone fracture, burns, effusion, joint link, hemarthrosis, concussion, cedea
 EMI2.5
 'and effusion of any genesis defQuiaee eonftitidn, nephrctt - ascites, thermal and solar edema), songelations,

     insect bites, snake bite (for support of specific therapy and cala.1 'pain), congestion in the
 EMI2.6
 '; "region of the small circulation, pulmonary # dèae ÏM yl Treatment of the central component and the component The use of epeilOB-aMcapM acid:, the relief of pain conditions after emiumélt" is particularly remarkable and effective. t convent, by a single injection of 10 cm3 of a 5% solution one obtains in

 <Desc / Clms Page number 3>

 
 EMI3.1
 bed camps (often tn qv..1C \ a .. ,, ',.' oÍ \ 4 ', lil:.,' ,,:, 'Ol,' da la,, t; 1 y:

   . 4;: ¯V. , e <. "" '.. ".. au, xr.,.' xrir, 4 or, arxn dan ur, artur ..odrx ', after xp oaian d, x hdx ra R,.,;, t. .;, r nt: u, an., non artaar. ionda. taraf ât rlrxi ut w'dbi; ,, tü ,,, .- ,.



  , 1 t epsilon-aainoeaproic acid, in dr '[i'r "i. Nrt # ore na rru, r ân i ba, i'xm, -tU.,'!. ', /,' ,,,. , sum th'r. can, 1 that 'causal. All xuaai ruâaNs intupli- target "t after .. 1 oonnaisaandtt actutllaa aur lt de acti0.0 quickly d. 3. ' & 0141 # pailon-aminooaprolqut, is 4naisio, .1q, uI activity in the pain (s) Caused by! ## bltasurea, distortions, dislocations., L ,. fraoturet, 1 wound of bru lurll, ItO, .... ,,;, j 'i!' ::, '; jJ ;;' 0.1 \ f0; J. ':'.



  L. do .., e., 1 & 'torrae 4 hi, t: U ..' at1n "ï. \ 'AOtc! .., ...: t silon-aminocaprolque are established each time according to the circumstances , In particular to calm the pain, or when for other reasons a particularly rapid or particularly intense action is desired (shock,
 EMI3.2
 asthma attack, biliary colic, poisonings, o * 4th pulmonary), we administered 10.0 cm3, 4 'an aqueous solution per intravenously (half in the case of children), For all the other indications mentioned it is sufficient in general,

  'in addition to an initial intravenous injection of 10 cm3 of a 5% solution give three times a day = 4 tablets at 0.25 g to maintain a lasting action; however, it may be necessary to repeat the intravenous injection every 24 to 48 hours,

       Wounds duos with burns epithlise particularly quickly under a bandage with
 EMI3.3
 ointment with 2% epsilon-aminooaprofe.ua acid (having a fat-free base), However, like ecxemas, they must not be treated only with a 2% ointment of acid
 EMI3.4
 from Ip811on-am: Lnocaprofqul. '. But always in combination par, t 'ra1e-oral.-10c al .. ".

    :; +: i,

 <Desc / Clms Page number 4>

 
 EMI4.1
 A oanetsti qus 1let 'can ri; tv ernridrablrtbv the dosage and that in certain indications one can achieve surprisingly increased activity when applying the a-
 EMI4.2
 help epsilon-minocaprotque in trosvbislairoli and our tv of '' ¯ 'composed easily decomposing tà,:, Iivo a ours consti-' '' '#;' killing, with substance $ to aatxvitl larqur. - v.:.



  For example, only 2 to 10% of the quantity of cornaâ 'dt toid4 # pflilon-aainocaproîqu should be stttltatnt in otrtaints eze conatances when the adnistrs mixed in the molar ratio with alpha-pheaylbutyzic acid, instead of mixture one can of course also use the compound of the two substances,

       11- * lon-aminocaproic acid
For the treatment of certain diseases of the bones and joints and in painful conditions in the region of the upper backbone, a particularly suitable agent has been found to be an injection solution of 25 mg of acid.
 EMI4.3
 nicotinic and 500 mg of epiilo-aminocaprolque acid in aqua per 10 cm3, The unpleasant side actions of nicotinic acid (abdominal cramps and pruritus)

   this form of administration is not manifested to us * As support of the therapy we can also administer a molar mixture of acid
 EMI4.4
 of opsiloamminocaprotque with b <ta-M <thylta <-Mdi * ne or nicotinic acid by oral role * @ Similar results are obtained in the case of
 EMI4.5
 the combination of epsilonaminooaprotqud acid AVOO urea, "; f choline or betatne perep * Ctiv ent during the application ;; of their corresponding compounds ## their compote corrwepondMtx .. rK;

   it 8 Y 8 li D 1 C d '1' Q! ! i. '-' "ll
1.preparation containing apsilonsaminne-caproic acid as agents for symptomatic or causal therapy

** ATTENTION ** end of DESC field can contain start of CLMS **.

Claims (1)

EMI4.6 de tumeurs maligne$ (comme par exemple 1< eMaw), d'affection :: <Desc/Clms Page number 5> EMI5.1 f:ptrtaohy ittttttt|'( d*ét tt p"'.t'..ii,iqÜ.j"'idta, brûlurii ..;Y'1;!:;U}i peiHMaatetM'aM ' ,>, :'::;'L<;::;'.i\:j;Í,':(:' {([\,; '. '2. ,Acide ',;nud.nocapl'Oqu. ,1\Ûvüt;' la r..'i.:;1:1V':" dication là utïào aous toilot dfune .olutoalqu.u...I'n,'tii1Ë blé ;: . ' /. : '# /#'##fii1 1:r:;i:,;;;" Acide 14, re :J('";,r't.,, une ,,',,!' "<'",; dieea'3., "'ilS.''fId.'lto't1Al.oli.d' ou dissout$ '' !"'/' raps.. orale., "."':'.'\'.': ' x ' ;J':' .:.;f';ii"" ,lu, AGic!." .p.l1oa.Qd.ftoeaprolqul .w.'&ft'l'\,r.Y.n4.;,!l:( . '\' , ,,' uttlittâ tous tome diu onpout '..' # !> ## d*ea | :";'':"'.... '1""""- # ( ; ; <,v ':' Acide .p.S.l0X'.WIIOOlpro!CI"t ou 1â,n"'H!- ,;i'; EMI4.6 malignant tumors $ (like for example 1 <eMaw), affection :: <Desc / Clms Page number 5> EMI5.1 f: ptrtaohy ittttttt | '(d * ét tt p "'. t '.. ii, iqÜ.j"' idta, burnurii ..; Y'1;!:; U} i peiHMaatetM'aM ',>,: '::;' L <; ::; '. I \: j; Í,' :(: '{([\ ,;'. '2., Acid',; nud.nocapl'Oqu., 1 \ Ûvüt; 'la r ..' i.:;1:1V ': "dication there utïào august dfune .olutoalqu.u ... I'n,' tii1Ë wheat;:. '/.:' # / # ' ## fii1 1: r:; i:, ;;; "Acid 14, re: J ('";, r't. ,, a ,,' ,,! '"<'" ,; dieea'3. , "'ilS.' 'fId.'lto't1Al.oli.d' or dissolve $ ''!" '/' raps .. oral., "." ':'. '\'. ':' x ' ; J ':'.:.; F '; ii "", lu, AGic !. ".p.l1oa.Qd.ftoeaprolqul .w.' & Ft'l '\, rYn4.;,! L :(. '\', ,, 'uttlittâ all tome diu onpout' .. '#!> ## d * ea |: ";' ':"' .... '1 "" "" - # (;; <, v ':' Acid .pS10X'.WIIOOlpro! CI "t or 1â, n" 'H! -,; i'; ettion 10 1!tiU... oOlllbillu.all avec de l'aoidt -,:pII""Î .±., bwtyfiqttti ' -,\ ' . */- ' S 6. Acide µ' pyoîqu* milieu (miaat..ftvwnaoiM. /, .,'-" proique utiusd oui vont ,.".ndioatioll :<" ",\,,,;,'::'i>'}'f;\ tt;:\ .' '." ' , 7. Acide IPdlon"am1DOoaprOa;utlÙ.IDtI"Vlftct!:;,}2;"," ' atiea 1, utiUté ta eombiaiitoa siYte/i'itld* niaoUnit. (; ':'"':;: ',!,.,,;. 'AoS.c!I.p.il0..¯l\ooapl'o",' .\d,ü, 1.t""dt..:tJÚ. 1 utilied, o,ô..bÙÛ'OI\&"'8 41 la ,b.t"1\f"';k;'!f jgfe prridiat.' # .. '....."...' .ic." .S;';; i::N:;'S:j:!'.1t\;\ ''.'.:.,'.9<'AeidëY &tic 10 utiU.1 ta J,ol\binai 1 Ofl , ou sou tome dé coxpo$4# av" Bt dt l'ur'." dl 1& ob.11e." ou 4', la bdtatnoo ¯ # ;; ];' ' # ; ettion 10 1! tiU ... oOlllbillu.all with aoidt - ,: pII "" Î. ±., bwtyfiqttti '-, \'. * / - 'S 6. Acid µ' pyoîqu * middle (miaat..ftvwnaoiM. /,., '- "proique utiusd yes go,.". Ndioatioll: <"", \ ,,,;,' :: ' i> '}' f; \ tt;: \. ''. "', 7. Acid IPdlon" am1DOoaprOa; utlÙ.IDtI "Vlftct!:;,} 2;", "' atiea 1, utiUté ta eombiaiitoa siYte / i'itld * niaoUnit. (; ':' "':;:',!,. ,,;. 'AoS.c! Ipil0..¯l \ ooapl'o",'. \ d, ü, 1 .t "" dt ..: tJÚ. 1 utilied, o, ô..bÙÛ'OI \ & "'8 41 la, bt" 1 \ f "'; k; '! f jgfe prridiat.' # .. ' ..... "... '.ic." .S;' ;; i :: N:; 'S: j:!'. 1t \; \ ''. '.:.,'. 9 < 'AeidëY & tic 10 utiU.1 ta J, ol \ binai 1 Ofl, or sou tome de coxpo $ 4 # av "Bt dt l'ur'." Dl 1 & ob.11e. "Or 4 ', la bdtatnoo ¯ # ;; ]; '' #;
BE647556A 1964-05-06 1964-05-06 BE647556A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BE647556A BE647556A (en) 1964-05-06 1964-05-06

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE647556A BE647556A (en) 1964-05-06 1964-05-06

Publications (1)

Publication Number Publication Date
BE647556A true BE647556A (en) 1964-08-31

Family

ID=3846496

Family Applications (1)

Application Number Title Priority Date Filing Date
BE647556A BE647556A (en) 1964-05-06 1964-05-06

Country Status (1)

Country Link
BE (1) BE647556A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007597A1 (en) * 1978-07-20 1980-02-06 Stiftung Deutsches Krebsforschungszentrum N-loweralkyl-glycinamides and sarcosine anhydride and their mixtures with known tumor-inhibiting compounds, sarcosin for use in the treatment of tumors, medicaments containing these compound and processes for their preparation
FR2531950A1 (en) * 1982-08-20 1984-02-24 Midit O-AMINO ACID AMIDE DERIVATIVES, THEIR PREPARATION, USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS AND CARDIOVASCULAR DISORDERS, AND COMPOSITIONS CONTAINING SAME

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007597A1 (en) * 1978-07-20 1980-02-06 Stiftung Deutsches Krebsforschungszentrum N-loweralkyl-glycinamides and sarcosine anhydride and their mixtures with known tumor-inhibiting compounds, sarcosin for use in the treatment of tumors, medicaments containing these compound and processes for their preparation
FR2531950A1 (en) * 1982-08-20 1984-02-24 Midit O-AMINO ACID AMIDE DERIVATIVES, THEIR PREPARATION, USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS AND CARDIOVASCULAR DISORDERS, AND COMPOSITIONS CONTAINING SAME

Similar Documents

Publication Publication Date Title
KR20000010847A (en) Antimicrobial composition for treatment of herpes simplex virus and other infectious diseases
WO2014188214A1 (en) Topical composition with ginger
EA009384B1 (en) Prostaglandin compositions and methods of treatment for male erectile dysfunction
JP5558573B2 (en) Topical formulation for diabetic foot ulcers
BE647556A (en)
US4985257A (en) Hemorrhoidal treatment and composition
JPH01299219A (en) Menfegol-containing drug for preventing infection with human immunodeficiency virus
PT683670E (en) WOUND HEALING COMPOSITIONS CONTAINING IODINE AND A REDUCING ACID
Madden The Surgery of Egypt
Sutherland et al. Local inactivation of funnel‐web spider (Atrax robustus) venom by first‐aid measures: potentially lifesaving part of treatment
US2095571A (en) Antiseptic
RU2367416C1 (en) Medicine for treatment of animals with puerperal endometritis
CN102293783B (en) Traditional Chinese medicinal composition for treating bedsore
US8236814B2 (en) Composition and method for treatment of warts
RU2181282C2 (en) Preparation for preventing and treating endometritis in cows
CN117357547A (en) Application of pharmaceutical composition in preparation of medicine for treating rheumatoid arthritis
RU2852842C1 (en) Composition with antiseptic, wound-healing and haemostatic effects for wound treatment in everyday life and in military field conditions
EP1647282A1 (en) Topical anti-inflammatory aqueous gel containing menthol, thymol and eucalyptol, process for their preparation and use of thereof
EP1516631A1 (en) Body ointment having decongestant effect and for the progressive relief of muscular pain, sprains, wrenchs, dislocations, aches and for relief of articular and rheumatic pain
US20210015965A1 (en) Means and methods for wound healing
RU2210365C1 (en) Agent for scabies treatment
CN103272042A (en) Smoked lotion for treating hemorrhoids and fistula
JPH02193929A (en) Diabete remedy
RU2580280C2 (en) Composition for local application for reduction or relief of pain syndrome
RU2682454C1 (en) Ointment for treatment of thermal burns and method for treatment thereof